Gregory studied pharmacology during his Ph.D. and he has cumulated 14 years of experience in cell biology, with the publication of 14 scientific articles. Gregory is a co-inventor of the technology of FluoSphera (patent).

Biotechnology engineer by training and holding a Ph.D. in Molecular Biology, Clelia implemented new methods of advanced microscopy to develop new cancer therapies at the University of Geneva and at the Max Planck Institute (Germany).

Igor did a Ph.D. in molecular biology followed by a post-doctoral training with Sir. Gregory Winter, Nobel Prize in Chemistry. Igor is the founder and former CEO of Selexis, a world-class leader in cell line development for drug discovery and development.

Kamel is a Medical Doctor with more than 30 years in drug innovation. Kamel is the former CEO of Debiopharm, a swiss drug development company, and he has evaluated hundreds of molecule candidates for drug development.

Jean-Pierre Pennacino has a proven track record in corporate finance, fund raising and public markets, as well as acumen in M&A. He currently serves as CFO for MedAlliance, a medical device company being acquired by Cordis for USD 1.1 billion.

Aurélien is a Professor of Biochemistry at the University of Geneva. Aurélien is an elected member of the EMBO, a Key Opinion Leader in cell encapsulation technology and a co-inventor of the technology of FluoSphera.

Gerardo is the Director of the Biomolecular Screening facility at the EPFL (Switzerland), implementing drug repurposing strategies and evaluating highly informative assays for drug screening.

Guido is the co-founder and CEO of Amphilix and he spent 20 years at Novartis as Director in Global Discovery Chemistry. Guido has led projects in different phases from target identification to early clinical stage.

Dimitri has a Ph.D. in Pharmacology and he installed the high-throughput screening facility ACCESS Geneva at the University of Geneva. Dimitri is a technical expert in the acquisition and analysis of high-content screening data.